Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva buys Allergan: 3 reasons why it's a blockbuster deal | Fortune
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - BNN Bloomberg
The Difficulties of Cloning a CEO - Bloomberg
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Teva (TEVA) Agrees to $225 Million Texas Opioid Settlement, AG Says - Bloomberg
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
ADHD Drug Adderall Supply Delays Likely to Continue for 2-3 Months, Teva Says - Bloomberg
Activist Investor Jana Partners Takes Stake in Teva, Report Says | Ctech
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Teva makes $40B offer for Mylan
Teva's Credit Rating Cut to Junk by Fitch - Bloomberg
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
Sandoz, Amneal and Rhodes join Teva in nationwide generic Adderall shortage as demand spikes
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says | Barron's
Teva Sees Adderall Supply Delays Continuing for 2-3 Months (1)
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Teva Loses CEO, Leaving Investors to Guess What's Next - Bloomberg
Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Drugmaker Teva makes $40B bid for rival Mylan
Teva looks to sell generics in China through joint venture with Guangzhou Pharma: Bloomberg | Fierce Pharma
